Café

© 2026 Longbridge｜Terms of Service Privacy Policy

MapLight Therapeutics

MPLT

9.90572.91% ( -26.655 )

Closed: Jul 27, 16:00:00 (EDT)

OverviewOverview OptionsOptions NewsNews PostsPosts FinancialsFinancials ForecastForecast ValuationValuation ShareholdersShareholders ProfileProfile

LongbridgeAI

MapLight Therapeutics plunges 71% as schizophrenia drug fails dosing test
US Stock Market Update·13 hours ago
MPLT-72.91%
MapLight Therapeutics plunges 68% as once-daily dosing test fails
US Stock Market Update·15 hours ago
MPLT-72.91%
12 Health Care Stocks Moving In Monday's Intraday Session
benzinga_article·16 hours ago
MPLT-72.91%PFSA-28.65%
MapLight Therapeutics plunges 62% as drug fails once-daily dosing test
US Stock Market Update·19 hours ago
MPLT-72.91%
12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga_article·21 hours ago
MPLT-72.91%MTNB+37.53%
MapLight says Phase 2 ZEPHYR trial shows ML-007C-MA cuts PANSS score in schizophrenia
PUBT·22 hours ago
MPLT-72.91%
MapLight Therapeutics (MPLT) Rally Puts Its CNS Story And Valuation In Focus
Simplywall·1 day ago, 08:08 PM
MPLT-72.91%
Maplight Therapeutics Chief Discovery Officer Anatol Kreitzer disposes of USD 1.34 million in common shares
PUBT·Jul 20 at 05:03 AM
MPLT-72.91%
MapLight Therapeutics Insiders Sold Shares Worth Over $6.7M
TradingView·Jul 17 at 08:50 PM
MPLT-72.91%
Maplight Therapeutics CMO Erin Pennock Foff sells USD 1.99 million in common shares
PUBT·Jul 17 at 08:44 PM
MPLT-72.91%
Analyst Reiterates Buy on MapLight Therapeutics, Maintains $45 Price Target Amid Optimism for ML-007C-MA
Tip Ranks·Jul 14 at 03:05 PM
MPLT-72.91%